Biosimilars: To switch or not to switch – that is the question

Infliximab or biosimilars in sarcoidosis; to switch or not to switch?

Sarcoidosis is a systemic, granulomatous disorder that can affect multiple organs and has a variable clinical course (1). Because the etiology of sarcoidosis remains unknown, no curative treatment exists. It is important to state that not all patients require treatment. In the literature the need for systemic treatment varies between 20-70% (2-4). Main treatment indications are risk of organ fa...

To SWiTCH or not to SWiTCH?

In this issue of Blood, Ware and Helms report results from the Stroke With Transfusions Changing To Hydroxyurea (SWiTCH) study designed to determine whether hydroxyurea is as effective as transfusions in preventing recurrent strokes in children with sickle cell anemia. The finding of strokes in 7 of 67 children receiving hydroxyurea but none in 66 children who received transfusions led the auth...

coeliac disease: to classify or not to classify – that is the question!

.

Direct oral anticoagulants: to switch or not to switch?

Fifty years after the introduction of vitamin K antagonists (VKAs) a novel group of oral anticoagulants has been introduced. The currently named direct oral anticoagulants (DOACs) represent a landmark in anticoagulant care. The direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and direct factor IIa inhibitors (dabigatran) are being prescribed more frequently, as both clinicians and ...

the student committee of sports medicine research center: to be independent or not to be? that is the question